CIMT Annual Meeting
May 21-23 CIMT 2019 Annual Meeting Mainz, Germany
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors
Three poster presentations will be given by the company and its collaborators Florence Atrafi, MD, a clinical investigator on the phase 1 NAPOLY study, has received a prestigious ASCO Merit Award in recognition of her abstract that highlights important research findings Maastricht, The Netherlands, 17 May 2019 – Cristal Therapeutics, a clinical-stage pharmaceutical company developing […]
Knowledge for Growth
May 9 Knowledge for Growth Ghent, Belgium
ESMO advanced ovarian cancer
February 22 ESMO advanced ovarian cancer Valencia, Spain
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline
Maastricht, The Netherlands, 2nd November 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO). […]
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
Maastricht, The Netherlands, 25th October 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer. CPC634 is a new drug […]
ESMO 36th Annual Congress 2018
October 19-23 ESMO 36th Annual Congress 2018 Munich, Germany
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
